The FDA on April 20, 2020, granted accelerated approval to PEMAZYRE® for the treatment of adults with previously treated, unresectable locally advanced or metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. PEMAZYRE® is a product of Incyte Corporation.
Bottom Ad
Advertisement
Subscribe
